Liberum cuts target price for Oxford Biomedica, saying it still lacks sufficient scale
(Sharecast News) - Analysts at Liberum cut their target price for shares Oxford Biomedica arguing that the company's pan-vector offering had yet to reach sufficient scale in order to deliver sustainable profitability.
Read more